Tvardi Therapeutics Inc. logo

Tvardi Therapeutics (TVRD) stock

TVRD · Tvardi Therapeutics Inc. · NASDAQ

Market cap
$13.2M
Shares out
13.3M

What is the latest news on TVRD stock?

SECago
Tvardi Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

8-K - Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830)

All TVRD news

When does Tvardi Therapeutics report earnings?

The latest Tvardi Therapeutics earnings release came out on Nov 13, 2026: Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update. Before that, Tvardi Therapeutics reported on Oct 13, 2025.

TVRD earnings history

Who owns the most TVRD stock?

Slate Path Capital LP was the largest reported holder of TVRD at the end of Q2 2026, with 704,118 shares worth $1.3 million. Next came Vanguard Capital Management LLC ($654K) and American Financial Group Inc ($425K). In all, 58 institutions reported $4.2 million of TVRD in their 13F filings.

All TVRD fund holders

Financial highlights

Full financials
Net income, TTM
-$26.66M
Cash
$22.27M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

Latest news

25 items
News · 26 weeks22+150%
2026-05-31: 02026-06-07: 12026-06-14: 02026-06-21: 02026-06-28: 02026-07-05: 42026-07-12: 22026-07-19: 02026-07-26: 22026-08-02: 02026-08-09: 42026-08-16: 02026-08-23: 12026-08-30: 02026-09-06: 02026-09-13: 02026-09-20: 12026-09-27: 02026-10-04: 02026-10-11: 12026-10-18: 12026-10-25: 02026-11-01: 02026-11-08: 32026-11-15: 22026-11-22: 0
2026-05-312026-11-22
Mix990d
  • Other4(44%)
  • SEC Filings3(33%)
  • Analyst1(11%)
  • Earnings1(11%)
Activity · 52 weeks5428 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Tvardi Therapeutics Inc. (TVRD) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for TVRD, including 3 SEC filings, 1 earnings update and 1 press release or news item. The most recent was published Nov 19, 2026.

TVRD FAQ

8 questions
  • Is TVRD profitable?
    No. Tvardi Therapeutics Inc. reported a net loss of $26.66M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does TVRD have?
    Tvardi Therapeutics Inc. reported $22.27M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does TVRD stock trade?
    Tvardi Therapeutics Inc. (TVRD) is listed on NASDAQ.
  • What sector and industry is TVRD in?
    Tvardi Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Tvardi Therapeutics Inc. go public?
    Tvardi Therapeutics Inc. (TVRD) completed its IPO in 2014.
  • What are analysts saying about TVRD?
    Across the last 8 analyst actions on Tvardi Therapeutics Inc., there were 2 upgrades and 4 downgrades. The most recent action was from Chardan Capital Markets: Buy with a $8.00 price target on 2026-10-20. Recent price targets range from $3.00 to $13.00.
  • What companies are similar to TVRD?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), ABT (Abbott Laboratories), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare TVRD side-by-side with any of them on Quantisnow.
  • How can I track TVRD on Quantisnow?
    Quantisnow aggregates Tvardi Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TVRD to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change